RxDoctor Payments Data

Howard Haverty

Richmond, VANPI 1942202882

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 288 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 46.1% of the total.

$4,982in general payments, 2019–2025

Across 288 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$576
  • Takeda Pharmaceuticals U.S.A., Inc.$455
  • Sanofi$324
  • Johnson & Johnson$319
  • Merck$249
  • plus $760 from 12 others

What the payments were for

  • Food & beverage$4,982100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole17$315

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →